D-0443-2024 Class III Terminated

Recalled by Novitium Pharma LLC — East Windsor, NJ

FDA drug recall D-0443-2024 was initiated by Novitium Pharma LLC on Mar 25, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated Jul 16, 2024). Affected quantity: 1,003 bottles.

Recall details

Product Type
Drugs
Report Date
Apr 24, 2024
Initiation Date
Mar 25, 2024
Termination Date
Jul 16, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,003 bottles

Product description

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10

Reason for recall

Failed Impurities/Degradation Specifications

Distribution pattern

U.S. Nationwide

Code information

Lot M23011A; Exp. 12/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0443-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0443-2024. Report a data issue: hello@regdatalab.com.